Case Reports in Dermatology,
Journal Year:
2022,
Volume and Issue:
14(1), P. 88 - 92
Published: April 21, 2022
An
increasing
number
of
checkpoint
inhibitor-induced
subacute
cutaneous
lupus
erythematosus
events
have
been
reported.
We
present
the
first
case
nivolumab-induced
discoid
in
a
patient
with
hepatocellular
carcinoma.
The
presents
violaceous
hypopigmented
plaques
on
pinna
bilaterally,
central
hyperpigmentation
posterior
neck,
and
other
face,
forearms,
hands.
For
management,
nivolumab
was
held
for
2
months,
Plaquenil
topical
steroids
were
added.
Nivolumab
resumed
no
further
progression
DLE
lesions
improvement
skin.
It
is
important
to
characterize
side
effects
effectively
manage
them.
Annals of the Rheumatic Diseases,
Journal Year:
2020,
Volume and Issue:
80(1), P. 36 - 48
Published: April 23, 2020
Rheumatic
and
musculoskeletal
immune-related
adverse
events
(irAEs)
are
observed
in
about
10%
of
patients
with
cancer
receiving
checkpoint
inhibitors
(CPIs).
Given
the
recent
emergence
these
lack
guidance
for
rheumatologists
addressing
them,
a
European
League
Against
Rheumatism
task
force
was
convened
to
harmonise
expert
opinion
regarding
their
identification
management.First,
group
formulated
research
questions
systematic
literature
review.
Then,
based
on
using
consensus
procedure,
4
overarching
principles
10
points
consider
were
developed.The
defined
role
management
irAEs,
highlighting
shared
decision-making
process
between
patients,
oncologists
rheumatologists.
The
inform
wide
spectrum
not
fulfilling
usual
classification
criteria
rheumatic
diseases,
differential
diagnoses.
Early
referral
facilitated
access
rheumatologist
recommended,
document
target
organ
inflammation.
Regarding
therapeutic,
three
treatment
escalations
defined:
(1)
local/systemic
glucocorticoids
if
symptoms
controlled
by
symptomatic
treatment,
then
tapered
lowest
efficient
dose,
(2)
conventional
synthetic
disease-modifying
antirheumatic
drugs,
case
inadequate
response
or
steroid
sparing
(3)
biological
severe
refractory
irAEs.
A
warning
has
been
made
myositis,
life-threatening
situation,
requiring
high
dose
close
monitoring.
For
pre-existing
disease,
baseline
immunosuppressive
regimen
should
be
kept
at
before
starting
immunotherapies.These
statements
provide
diagnosis
irAEs
aim
support
future
international
collaborations.
Current Drug Safety,
Journal Year:
2018,
Volume and Issue:
13(3), P. 150 - 164
Published: May 10, 2018
Immune
checkpoint
inhibitors
are
a
new
promising
class
of
antitumor
drugs
that
have
been
associated
with
number
immune-related
Adverse
Events
(AEs),
including
musculoskeletal
and
rheumatic
disease.We
searched
Medline
reviewing
reports
AEs
induced
by
immune
inhibitors.Several
treatment
reported
in
the
literature.
In
particular,
arthralgia
myalgia
were
most
common
AEs,
whereas
prevalence
arthritis,
myositis
vasculitis
is
less
characterized
mainly
case
series
reports.
Other
occasionally
described
sicca
syndrome,
polymyalgia
rheumatica,
systemic
lupus
erythematosus
sarcoidosis.Newly
diseases
frequent
adverse
event
treatment.
Lara D. Veeken,
Journal Year:
2019,
Volume and Issue:
58(Supplement_7), P. vii40 - vii48
Published: July 9, 2019
Abstract
Immune
checkpoint
inhibitors
have
advanced
the
treatment
paradigm
of
various
cancers,
achieving
remarkable
survival
benefits.
However,
a
myriad
immune-related
adverse
events
(irAE)
has
been
recognized
in
almost
every
organ
system,
presumably
because
persistent
immune
system
activation.
Rheumatic
symptoms
such
as
arthralgia
or
myalgia
are
very
common.
More
specific
irAE
increasingly
being
reported.
The
most
frequent
ones
inflammatory
arthritis,
polymyalgia-like
syndromes,
myositis
and
sicca
manifestations.
These
rheumatic
can
develop
∼5–10%
patients
treated
with
inhibitors,
although
true
incidence
rates
cannot
be
estimated
given
lack
prospective
cohort
studies,
likely
underreporting
oncology
trials.
In
this
review,
we
will
provide
summary
epidemiologic
data
reported
for
these
irAE,
until
more
robust
longitudinal
studies
become
available
to
further
define
rate
receiving
novel
cancer
therapies.
Lara D. Veeken,
Journal Year:
2019,
Volume and Issue:
58(Supplement_7), P. vii68 - vii74
Published: June 27, 2019
Abstract
Compared
with
conventional
cancer
therapies,
the
spectrum
of
toxicities
observed
checkpoint
inhibitors
is
unique
and
can
affect
any
organ
system.
Arthralgia
myalgia
were
by
far
most
commonly
reported
rheumatic
immune-related
adverse
events
in
clinical
trials,
there
now
a
growing
number
case
series
reports
describing
features
de
novo
events,
which
will
be
focus
this
review.
Some
patients
develop
genuine
classic
musculoskeletal
diseases,
but
mimic
diseases
atypical
features,
mainly
polymyalgia
rheumatica,
rheumatoid
arthritis
myositis,
as
well
several
systemic
conditions,
including
sicca
syndrome,
vasculitis,
sarcoidosis,
sclerosis
lupus.
Melanoma Research,
Journal Year:
2018,
Volume and Issue:
29(2), P. 212 - 215
Published: Nov. 26, 2018
Nivolumab
is
widely
used
to
treat
several
late-stage
malignancies
such
as
melanoma
and
non-small-cell
lung
cancer
by
inhibiting
the
interaction
between
programmed
cell
death
protein-1
its
ligand.
By
stimulating
an
antitumor
immune
response,
it
also
leads
adverse
events.
Here.
we
report
two
cases
of
subacute
cutaneous
lupus
erythematosus
(SCLE)
induced
nivolumab.
Case
1:
a
72-year-old
woman
with
stage
IV
melanoma.
Two
months
after
nivolumab
discontinuation
because
autoimmune
hepatitis,
patient
was
in
complete
remission
pruritic
nummular
erythematous
plaques
appeared
on
back
arms.
2:
43-year-old
man
put
under
for
metastatic
cancer.
After
cycles,
annular
eruption
hands,
arms,
chest.
The
hypothesis
SCLE
confirmed
biopsies
showing
lymphoid
perivascular
inflammatory
infiltrates,
scarce
C3
deposits
along
basal
layer
epidermis
2.
Both
patients
tested
positive
antinuclear
antibodies
anti-SSA
antibodies.
Lesions
were
regressive
topical
corticosteroids
hydroxychloroquine
first
oral
prednisone
second
patient.
No
systemic
involvement
observed.
occurrence
2
evidence
that
drug
effect
prolonged
maintenance
reception
saturation
months.
A
causal
relationship
suggested
(i)
at
least
(ii)
regression
lesions
following
treatment
hydroxychloroquine,
(iii)
fact
our
